Northwire Canada EditionThursday, October 15, 2026
Sign inSubscribe
Northwire
⌕
GOLD 4107.90 −1.7% SILVER 55.88 −6.1% COPPER 6.62 −1.6% OIL 95.09 +1.0% PALLADIUM 1096.50 −2.7% CIA 2.64 −0.4% BTO 7.09 −4.3% MCI 0.155 +0.0% CAN 0.065 +0.0% BLDS 0.335 +8.1% SAO 0.050 +0.0% SF 0.315 +0.0% BEA 0.055 −15.4% BMM 3.90 +11.1% AUGC 0.295 −13.2% MFG 3.34 −3.8% CDE 21.33 −7.7% CYG 0.160 −5.9% RSMX 0.100 −4.8% TUF 0.830 −5.7% GPG 0.285 −3.4% GOLD 4107.90 −1.7% SILVER 55.88 −6.1% COPPER 6.62 −1.6% OIL 95.09 +1.0% PALLADIUM 1096.50 −2.7% CIA 2.64 −0.4% BTO 7.09 −4.3% MCI 0.155 +0.0% CAN 0.065 +0.0% BLDS 0.335 +8.1% SAO 0.050 +0.0% SF 0.315 +0.0% BEA 0.055 −15.4% BMM 3.90 +11.1% AUGC 0.295 −13.2% MFG 3.34 −3.8% CDE 21.33 −7.7% CYG 0.160 −5.9% RSMX 0.100 −4.8% TUF 0.830 −5.7% GPG 0.285 −3.4%
M&A / Property Neutral

EnWave Signs Technology Evaluation and License Option Agreement with Swiss Cannabis Selection AG, Announces Significant Evaluation Results

EnWave's recurring TELOA pipeline masks persistent revenue volatility and cash burn; skepticism already discounted.

By The Northwire Desk — AI Analysis Jun 08, 2026 · 09:00 ENW · 0.235 EnWave Corporation
Executive Summary
  • EnWave Corporation entered into a Technology Evaluation and License Option Agreement (TELOA) with Swiss Cannabis Selection AG (SCS) and Schibano Pharma AG.
  • The agreement allows SCS to evaluate EnWave's proprietary REV™ dehydration technology for medical cannabis and botanical products.
  • Independent testing demonstrated a 2-5 day reduction in drying times without compromising cannabinoid potency, sensory quality, or safety profiles.
  • SCS holds the option to enter a commercial license agreement upon successful completion of the evaluation program.
  • No financial terms, upfront payments, or royalty structures were disclosed.
  • Evaluation activities are expected to commence in the coming months.
Material Impact
  • The TELOA is routine business development consistent with EnWave's historical pattern of signing evaluation agreements. It contains no financial terms, upfront payments, or guaranteed royalties. Given the stock's -27.3% decline since the last earnings print, skepticism about revenue volatility and cash burn was already heavily discounted. The news does not alter the fundamental trajectory or provide near-term cash flow visibility. It is Routine - Neutral.
ENW · Price
Company Overview
  • EnWave Corporation develops and licenses proprietary Radiant Energy Vacuum (REV™) dehydration technology.
  • The business model centers on selling equipment and signing royalty-bearing commercial licenses with food, cannabis, and botanical producers.
  • The company maintains a global footprint with partners across 26 countries, focusing on operational efficiency and product quality preservation.
Read the original news release →

More from EnWave Corporation

May 22, 2026 · 09:00

EnWave’s elephant-hunt partnership with a $20B giant can’t mask the gaping hole in quarterly machine sales and a return to cash‑burn that threatens to swallow the balance sheet.

Earnings May 22, 2026 · 08:30

EnWave Partners with $20B Food Behemoth to Test REV Drying Technology, Betting on a Royalty Windfall

M&A / Property Apr 15, 2026 · 09:00

Egypt Expansion Validates Global Licensing Model

Other Apr 07, 2026 · 09:00

## What the news says

M&A / Property Mar 10, 2026 · 23:29

EnWave signs licence deal with Teagasc

M&A / Property Mar 10, 2026 · 09:00

EnWave Signs License Agreement, and Equipment Purchase Agreement with Teagasc, the Agricultural and Food Development Authority of Ireland

Other